Alzheimer’s Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The alzheimer’s disease market reached a value of USD 3,194.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4,955.5 Million by 2035, exhibiting a growth rate (CAGR) of 3% during 2025-2035.

The Alzheimer’s disease market has been comprehensively analyzed in IMARC's new report titled "Alzheimer’s Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Alzheimer's disease (AD) refers to a neurodegenerative disorder characterized by the degeneration of nerve cells in several areas of the brain that control thought, memory, and language. The most common symptoms include memory impairment, depression, loss of inhibitions, etc. As the disease progresses, symptoms may include issues with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral problems. Alzheimer’s disease currently represents the seventh leading cause of death among all diseases and one of the biggest causes of disability and dependency among the geriatric population. Alzheimer’s disease has physical, psychological, social, and economic impacts, not only for individuals living with the disease, but also for their careers, families, and society at large.

The Alzheimer’s disease market is primarily driven by a rising geriatric population, who are more prone to neurodegenerative disorders. In over 90% of patients with Alzheimer’s, symptoms do not appear till the age 60. Furthermore, incidence of the disease rises with age and doubles every 5 years after age 65. In addition to the rising ageing population, Alzheimer’s disease market is also driven by improving diagnosis and drug treatment rates which includes a rising adoption of newer diagnostic techniques for early diagnosis. Furthermore, the ongoing development of several novel therapeutics that have a strong safety and efficacy profile is also expected to catalyze the growth of the market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Alzheimer’s disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Alzheimer’s disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Alzheimer’s disease market in any manner.

Recent Developments:

• In January 2025, Eisai and Biogen announced that the U.S. FDA had approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
• In August 2024, Coya Therapeutics stated that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer’s Association would be presented at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (CTAD24).
• In April 2024, Eisai Co., Ltd. and Biogen Inc. jointly announced that Eisai had filed a supplemental biologics license application to the U.S. FDA for monthly intravenous (IV) maintenance dosing of lecanemab-irmb (U.S. brand name: LEQEMBI). LEQEMBI is indicated to treat Alzheimer's disease in people with mild dementia or cognitive impairment.
• In March 2024, TauRx Pharmaceuticals Ltd. released results from a prespecified examination of the phase 3 LUCIDITY trial, which measured the impact of hydromethylthionine mesylate (HMTM) on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration. The results revealed that HMTM combines two independent modes of action: inhibition of tau aggregation pathology in the brain and a second symptomatic activity.
• In February 2024, GSK and Alector announced the initiation of the global PROGRESS-AD Phase II clinical trial of AL101 in people with early Alzheimer's disease, including mild cognitive impairment and mild dementia due to AD.
• In February 2024, a study by Matthew Adesuyan et al. suggested that the use of phosphodiesterase type 5 inhibitors may be associated with a reduced risk of incident AD in men. Researchers are reporting that erectile dysfunction drugs increase blood flow, which could help lower the risk of Alzheimer's.
• In July 2023, Eli Lilly and Company disclosed findings from the TRAILBLAZER-ALZ 2 study, a phase 3 clinical trial analyzing the efficacy and safety of the N3pG antibody (donanemab) in participants with early symptomatic AD. The study revealed that donanemab effectively decelerated cognitive and functional decline in individuals exhibiting early signs of the disease.

Key Highlights:

• Alzheimer’s disease is the most common form of dementia, causing up to 70% of the 55 million dementia cases worldwide.
• About 1% of cases of Alzheimer's disease are entirely caused by genes, and other genes increase the risk of developing Alzheimer's.
• An estimated 6.9 million Americans aged 65 and older are living with Alzheimer's dementia in 2024.
• Estimates suggest that 50% or more of people living with Down syndrome will develop Alzheimer's with symptoms appearing in their 50s and 60s.
• A meta-analysis examining the incidence of Alzheimer's disease in Europe found that approximately 13 women out of 1,000 developed Alzheimer's each year, compared to only seven men.

Drugs:

Leqembi (lecanemab) is a monoclonal antibody that treats early Alzheimer's disease by targeting and reducing harmful amyloid-beta (Aβ) aggregates in the brain. Specifically, it binds to both soluble Aβ protofibrils and insoluble Aβ plaques, thereby reducing their presence and potentially slowing the progression of the disease.

Namenda is an FDA-approved drug for managing symptoms associated with moderate to severe stages of Alzheimer's disease. Its mechanism involves diminishing the levels of the neurotransmitter glutamate in the brain. This therapeutic agent can be administered independently or in conjunction with a cholinesterase inhibitor.

Remternetug's mechanism of action involves targeting and removing aggregated pyroglutamated amyloid-beta (Aβ) plaques, a key pathological feature of Alzheimer's disease. This investigational monoclonal antibody, from Eli Lilly and Company, uses microglia-mediated clearance to clear these harmful plaques from the brain, similar to the approach used by donanemab. By reducing these amyloid plaques, remternetug aims to modify the course of Alzheimer's disease.

COYA 301 is under development by Coya Therapeutics for the treatment of AD. It is administered through a subcutaneous route. The therapeutic candidate is a combination immunotherapy designed to lower activated T effector cells and activated macrophages/microglia while increasing peripheral T cell regulatory (Treg) function and numbers.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Alzheimer’s disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Alzheimer’s disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alzheimer’s disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Alzheimer’s disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Alzheimer’s disease across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Alzheimer’s disease across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of Alzheimer’s disease across the seven major markets?
• What is the number of incident cases (2019-2035) of Alzheimer’s disease by age across the seven major markets?
• What is the number of incident cases (2019-2035) of Alzheimer’s disease by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of Alzheimer’s disease by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Alzheimer’s disease across the seven major markets?
• What is the size of the Alzheimer’s disease patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend Alzheimer’s disease of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Alzheimer’s disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Alzheimer’s disease market?
• What are the key regulatory events related to the Alzheimer’s disease market?
• What is the structure of clinical trial landscape by status related to the Alzheimer’s disease market?
• What is the structure of clinical trial landscape by phase related to the Alzheimer’s disease market?
• What is the structure of clinical trial landscape by route of administration related to the Alzheimer’s disease market?